The old mainstay for prevention of stroke in patients with atrial fibrillation, warfarin (or Coumadin) may be further pushed aside by newer options based on the findings of a study published in the journal Stroke this month. Warfarin is a difficult drug because it requires frequent monitoring due to poor predictability of effect.